US011246921B2

(12) **United States Patent**
Contorni et al.

(10) **Patent No.: US 11,246,921 B2**
(45) **Date of Patent: *Feb. 15, 2022**

(54) **INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE**

(71) Applicant: **Seqirus UK Limited**, Berkshire (GB)

(72) Inventors: **Mario Contorni**, Siena (IT); **Derek O'Hagan**, Cambridge, MA (US); **Nicola Groth**, Buonconvento (IT)

(73) Assignee: **Seqirus UK Limited**, Berkshire (GB)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **16/452,783**

(22) Filed: **Jun. 26, 2019**

(65) **Prior Publication Data**

US 2020/0155664 A1 May 21, 2020

Related U.S. Application Data

(63) Continuation of application No. 16/178,897, filed on Nov. 2, 2018, now abandoned, which is a continuation of application No. 15/007,719, filed on Jan. 27, 2016, now Pat. No. 10,149,901, which is a continuation of application No. 13/148,939, filed as application No. PCT/IB2010/000312 on Feb. 10, 2010, now Pat. No. 9,278,126.

(60) Provisional application No. 61/207,385, filed on Feb. 10, 2009.

(51) **Int. Cl.**

A61K 39/145	(2006.01)
C12N 7/00	(2006.01)
A61K 39/12	(2006.01)
A61K 39/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 39/145*** (2013.01); ***A61K 39/12*** (2013.01); ***C12N 7/00*** (2013.01); *A61K 2039/545* (2013.01); *A61K 2039/55566* (2013.01); *A61K 2039/70* (2013.01); *C12N 2760/16134* (2013.01); *C12N 2760/16234* (2013.01)

(58) **Field of Classification Search**

CPC A61K 39/145; A61K 2039/55566; A61K 2039/70; A61K 47/06; A61K 9/1075; A61P 31/16; A61P 37/04; A61P 39/00; A61P 31/04

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,500,513	A	2/1985	Brown et al.
5,162,112	A	11/1992	Oxford et al.
5,580,767	A	12/1996	Cowsert et al.
5,750,110	A	5/1998	Prieels et al.
5,762,939	A	6/1998	Smith et al.
5,776,468	A	7/1998	Hauser
5,824,536	A	10/1998	Webster et al.
5,948,410	A	9/1999	Van Scharrenburg et al.
6,136,321	A	10/2000	Barrett et al.
6,245,532	B1	6/2001	Smith et al.
6,299,884	B1	10/2001	Van Nest et al.
6,334,856	B1	1/2002	Allen et al.
6,372,223	B1	4/2002	Kistner et al.
6,372,227	B1	4/2002	Garcon et al.
6,451,325	B1	9/2002	Van Nest et al.
6,506,386	B1	1/2003	Friede et al.
6,544,518	B1	4/2003	Friede et al.
6,861,410	B1	3/2005	Ott et al.
6,869,607	B1	3/2005	Buschle et al.
6,951,754	B2	10/2005	Hoffmann
7,316,813	B2	1/2008	Eichhorn
7,357,936	B1	4/2008	Garcon
7,384,642	B2	6/2008	Minke et al.
7,425,336	B2	9/2008	Minke et al.
7,566,458	B2	7/2009	Yang et al.
7,588,774	B2	9/2009	Campbell et al.
7,641,911	B2	1/2010	Ott et al.
7,959,931	B2	6/2011	Colegate et al.
8,206,749	B1	6/2012	O'Hagan et al.
8,309,139	B2	11/2012	O'Hagan et al.
8,506,966	B2	8/2013	Podda et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA	1122527	4/1982
CA	2235257	4/1997

(Continued)

OTHER PUBLICATIONS

Advisory Action dated Apr. 30, 2014, for U.S. Appl. No. 12/448,057, filed Dec. 5, 2007, 4 pages.

(Continued)

Primary Examiner — Bao Q Li

(74) *Attorney, Agent, or Firm* — Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

(57) **ABSTRACT**

Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 μg/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.

20 Claims, No Drawings